<DOC>
	<DOCNO>NCT00608517</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total-body irradiation donor umbilical cord blood transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving tacrolimus mycophenolate mofetil transplant may stop happen . PURPOSE : To look ability umbilical cord blood cell one two unrelated donor serve source stem cell people need bone marrow transplant .</brief_summary>
	<brief_title>Treatment Single Double Umbilical Cord Trans + Graft-versus-host Disease ( GVHD ) Prophylaxis w/ Tacrolimus &amp; Mycophenolate Mofetil</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine safety ( assessed day 100 non-relapse mortality ) feasibility single double umbilical cord stem cell transplantation patient hematological malignancy receive graft-versus-host disease ( GVHD ) prophylaxis comprise tacrolimus mycophenolate mofetil ( MMF ) . Secondary - To assess sustain donor engraftment , neutrophil recovery , platelet recovery , incidence severity acute graft-versus-host disease ( GVHD ) chronic GVHD , relapse rate , 100-day all-cause mortality , overall survival , immune reconstitution single double umbilical cord stem cell transplantation patient hematologic malignancy receive graft-versus-host disease ( GVHD ) prophylaxis comprise tacrolimus mycophenolate mofetil ( MMF ) . OUTLINE : - Conditioning : Patients receive myeloablative reduced-intensity conditioning regimen accord age prior treatment . - Myeloablative conditioning ( pediatric patient ) : Patients undergo total-body irradiation day -7 -4 , receive cyclophosphamide IV 1 hour day -3 -2 , methylprednisolone IV twice daily day -3 -1 , anti-thymocyte globulin IV 4 hour day -3 -1 . - Myeloablative conditioning ( adult patient 18-40 year old ) : Patients receive fludarabine phosphate IV 30 minute day -6 -4 , cyclophosphamide IV 1 hour day -5 -4 , undergo total-body irradiation day -3 -1 . - Reduced-intensity conditioning ( patient 40 50 year old OR deem ineligible myeloablative conditioning regimen due previous treatment ) : Patients receive fludarabine phosphate IV 30 minute day -6 -2 cyclophosphamide IV 1 hour day -6 undergo total-body irradiation day -1 . - Umbilical cord blood transplantation ( UCBT ) : All patient undergo single- double-unit umbilical cord blood transplantation ( UCBT ) day 0 . - Graft-versus-host disease prophylaxis : Patients receive tacrolimus IV continuously orally twice daily day -2 180 follow taper mycophenolate mofetil IV orally twice daily day 0-100 followed taper next 3 month . Patients also receive filgrastim ( G-CSF ) IV subcutaneously begin day 0* continue blood count recover . NOTE : *In adult patient receive reduced intensity transplant , G-CSF start total white cell count fall 2.5 x 109/L . After completion study treatment , patient follow monthly 1 year every 2-4 month thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patient UCB Unit Selection : General ( Adults Pediatrics ) Only one follow present : Acute leukemia ( lymphocytic myeloid undifferentiated biphenotypic ) complete remission 2 beyond Acute lymphocytic leukemia , Philadelphia chromosome positive complete remission 1 beyond Acute myeloid leukemia complete remission 1 evolve myeloproliferative disorder ( MPD ) myelodysplastic syndrome ( MDS ) . Acute leukemia complete remission 1 failure recover normal blood count development MDS follow induction chemotherapy . Therapy related acute leukemia complete remission 1 beyond Chronic myeloid leukemia ( CML ) chronic phase1 ( imatinib failure , imatinib intolerance ) , CML beyond first chronic phase Myelodysplastic syndrome ( Intermediate 1 high risk IPSS ) Therapy relate MDS ( irrespective IPSS ) Multiple myeloma must prior chemotherapy autologous transplant Chronic lymphocytic leukemia must fail two line conventional therapy still chemosensitive third line therapy . Chemosensitive NonHodgkin 's lymphoma Hodgkin 's lymphoma CR PR fail induction therapy . High risk acute leukemia/lymphoma eg Nk/T cell , HTLV associate leukemia/lymphoma , T cell lymphoma/leukemia first best response For patient acute leukemiathey must remission ( less 5 % leukemic marrow blast ) time study entry . Inclusion Criteria ( Adults 18 year old ) Karnofsky score &gt; 70 % Estimated creatinine clearance &gt; 60 ml/min Left ventricular ejection fraction &gt; 50 % Pulmonary function test DLCO , FEV1 FVC &gt; 60 % Total bilirubin SGOT &lt; 3.0 x upper limit normal Note : Age 18 40 year adult myeloablative conditioning Age &gt; 40 50 year adult reduce intensity conditioning Inclusion Criteria ( Pediatrics 18 year young ) Karnofsky Lansky score &gt; 70 % Estimated Creatinine clearance &gt; 60 ml/min Left ventricular ejection fraction &gt; 50 % Pulmonary function test FEV1 FVC &gt; 60 % ( patient &gt; 6 year age ) Total bilirubin SGOT &lt; 3.0 x upper limit normal Note : All pediatric patient receive myeloablative conditioning Inclusion Criteria Donor Issues No available HLA identical 1 antigen/allele mismatch ( Class IA , B Class II DR locus ) relate donor Umbilical Cord Blood UnitHLA Typing At least HLA 4/6 match ( Class IA , B low resolution , Class IIDR high resolution ) recipient For double UCB SCT unit least 4/6 match ( Class IA , B low resolution , Class IIDR high resolution ) recipient , least 4/6 match ( Class IA , B low resolution , Class IIDR high resolution ) Umbilical Cord Blood UnitCell dose For Single UCB SCT : unit ≥ 3.5 X 107 NC/kg recipient body weight ( For pediatric patient cell dose ≥ 3.0 X 107 NC/kg recipient body weight acceptable ) . Recipient body weight determine per standard guideline . For Double UCB SCT : ( do single UCB unit ≥ 3.5 X 107 NC/kg recipient body weight available adult , ≥ 3.0 X 107 NC/kg recipient body weight available pediatric patient ) The large two unit ( UCB1 ) minimum cell dose 2.0 X 107 NC/kg recipient body weight . The small two unit ( UCB2 ) minimum 0.5 X 107 NC/kg recipient body weight . The total cell dose UCB1 + UCB2 ≥ 2.5 X 107 NC/kg recipient body weight . Adult patient eligible double UCB SCT without appropriate second UCB unit enrol study single UCB unit contain ≥ 2.5 x 107 NC/kg recipient body weight . Exclusion Criteria Organ dysfunction per standard guideline . Unable give inform consent ( adult ) Pregnant lactate Sexually active individual capable become pregnant causing pregnancy unable unwilling use appropriate contraceptive . Active use illicit drug evidence positive toxicology screen substance prescribe medical professional prior initiate preparative regimen Actively smoke evidence positive nicotine screen prior initiate preparative regimen HIV positive Patients unrelated malignancy exclude except : diagnosis skin cancer ( squamous cell basal cell ) diagnosis cervical dysplasia ( CIN IIII ) malignancy currently remission treat curative intent 5 year precede study entry In patient secondary MDS secondary acute leukemiasthe previous nonhematopoietic neoplasm remission within 5 year study entry</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult non-Hodgkin lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia</keyword>
	<keyword>Philadelphia chromosome positive childhood precursor acute lymphoblastic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
</DOC>